Target Price | $10.20 |
Price | $1.95 |
Potential |
423.08%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Entera Bio Ltd. 2026 .
The average Entera Bio Ltd. target price is $10.20.
This is
423.08%
register free of charge
$10.50
438.46%
register free of charge
$10.10
417.95%
register free of charge
|
|
A rating was issued by 7 analysts: 6 Analysts recommend Entera Bio Ltd. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Entera Bio Ltd. stock has an average upside potential 2026 of
423.08%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.25 | -0.56 |
19.35% | 124.00% | |
P/E | negative |
3 Analysts have issued a Entera Bio Ltd. forecast for earnings per share. The average Entera Bio Ltd. EPS is
This results in the following potential growth metrics and future valuations:
2024 | $-0.25 | 19.35% |
---|---|---|
2025 |
$-0.56
124.00%
Unlock
|
Current | -8.26 | 13.84% |
---|---|---|
2025 |
-3.39
58.96%
Unlock
|
Entera Bio Ltd....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 07 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 27 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 18 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 07 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 27 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.